PrEP method switching: will it yield greater coverage of HIV protection? Applying lessons learned from family planning to guide future research in the context of PrEP …

C McGuire, MA Atieno, T Hoke, P Jeckonia… - Current HIV/AIDS …, 2024 - Springer
Abstract Purpose of Review Despite the growing availability of oral PrEP, coverage remains
suboptimal. Through the introduction of additional PrEP methods, including vaginal rings …

Financing and delivering pre-exposure prophylaxis (PrEP) to end the HIV epidemic

A Killelea, J Johnson, DT Dangerfield II… - Journal of Law …, 2022 - cambridge.org
The US has the tools to end the HIV epidemic, but progress has stagnated. A major gap in
US efforts to address HIV is the under-utilization of medications that can virtually eliminate …

Data Velocity in HIV-Related Implementation Research: Estimating Time From Funding to Publication

SR Schwartz, JC Ortiz, JD Smith, LK Beres… - JAIDS Journal of …, 2022 - journals.lww.com
Background: Given available effective biomedical and behavioral prevention and treatment
interventions, HIV-related implementation research (IR) is expanding. The rapid generation …

Causal effects of stochastic PrEP interventions on HIV incidence among men who have sex with men

A Sewak, S Lodi, X Li, D Shu, L Wen… - American journal of …, 2024 - academic.oup.com
Antiretroviral preexposure prophylaxis (PrEP) is highly effective in preventing human
immunodeficiency virus (HIV) infection, but uptake has been limited and inequitable …

Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus …

AS Rivera, K Pak, MT Mefford… - Open Forum Infectious …, 2024 - academic.oup.com
Background Tenofovir alafenamide fumarate (TAF) was promoted as a safer alternative to
tenofovir disoproxil fumarate (TDF) for human immunodeficiency virus oral preexposure …

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis

A Rivera, M Mefford, KJ Pak… - Open Forum Infectious …, 2023 - academic.oup.com
Abstract Background In October 2019, tenofovir alafenamide fumarate (TAF) was approved
for oral pre-exposure prophylaxis (PrEP) for preventing human immunodeficiency virus (HIV) …

Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic

JM Sharfstein - 2030 - HeinOnline
The US has the tools to end the HIV epidemic, but progress has stagnated. A major gap in
US efforts to address HIV is the under-utilization of medications that can virtually eliminate …